Kojin: Kojin Therapeutics Debuts to Solve Difficult Diseases Through Cell Behavior
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
Read full article »
Kojin is a Massachusetts-based biotechnology company that researches and develops cell-state biological therapeutics for the treatment of cancer, ischemia and fibrosis.
Read more